Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
Mort JF, Brighton D, DiBenedetto S, Wells L, Clark SM, Reid J, Patel I, Jackson C, Yelvington B, Miller R, Perciavalle M, Walsh K, Wolfe H, Locke SC, Zeidner JF, Duong VH, Reed DR, Dholaria B, LeBlanc TW, Keng M, Horton B, El Chaer F.
Mort JF, et al. Among authors: perciavalle m.
Eur J Haematol. 2024 Nov 27. doi: 10.1111/ejh.14354. Online ahead of print.
Eur J Haematol. 2024.
PMID: 39601208